Secure your source for quality antibody production. Learn how our experience and flexibility can meet your needs for both small scale and large scale production.
Developing Antibody Drug Conjugate (ADC) therapeutics? Inotiv has mass spectrometry assays to quantify your ADC target protein in any sample type, including FFPE tissue, without antibodies. We have developed assays to 27 ADC targets for oncology and other therapeutic applications.
Inotiv provides the broadest range of research models and related services to pharmaceutical and biotech companies, government, academia, and other life science organizations.
November 9-13, 2025 Long Beach, CA Booth #1613 Each fall since 1950, the American Association for Laboratory Animal Science has held its annual National Meeting. During the five da...
November 15-19, 2025 San Diego, CA Booth #2135 Each year, scientists from around the world congregate to discover new ideas, share their research, and experience the best the field...
November 16-19, 2025 Phoenix, AZ Booth #507 ACT is a global community of professional scientists representing the pharmaceutical and biotech industries, regulatory agencies, contra...
August 6, 2025 In a release issued under the same headline on August 6, 2025 by Inotiv, Inc. (NASDAQ: NOTV), please note that the amount of the recent draw request on the r...
Due to the current FDA concern and guidance on reducing the risk of Nitrosamine impurities in human drugs, there has been an increased industry need for testing of these impurities using the Bacterial Reverse Mutation (Ames) test. As Nitrosamines are not readily detectable by standard Ames methodologies, specifically cited in the Ames testing guideline (OECD 471), the need for a robust protocol better suited for this class of compounds is warranted.
General Toxicology
Histology
Pathology
DMPK
Consulting
Research Models
Research Model Services
Teklad Diet and Bedding
